Interactive Transcript
0:01
So, why prostate MRI as opposed to, say,
0:06
ultrasound or digital examination or serum PSA?
0:11
Well, first of all, serum PSA has a sensitivity
0:15
of 36 percent for diagnosing prostate cancer.
0:19
That, frankly, is not good enough.
0:22
Digital rectal examination is
0:24
somewhere far south of that.
0:27
And in terms of assessing tumors, we use
0:31
histologic rating called the Gleason score.
0:33
We'll talk about that at a separate time, but,
0:38
uh, a Gleason score of seven or over is considered
0:41
more aggressive; six or less, less aggressive,
0:44
and that'll be a story for another section.
0:47
Previously, we used transurethral rectal
0:50
ultrasound to biopsy and define aggressiveness
0:55
of the lesion with the histologic Gleason,
0:57
Gleason score, but those biopsies were not
1:00
directed to any one specific ominous locus.
1:05
They are somewhat random in
1:07
character until MRI came along.
1:10
So what are the indications for MRI?
1:12
Probably the most important indication is
1:15
surveillance in a low-risk Tier 1 individual.
1:20
So, what does a Tier 1 mean?
1:23
That is a separate vignette coming right up.
1:25
But we're going to have three
1:27
tiers of aggressiveness and risk.
1:30
There'll be Tier 1, Tier 2, and Tier 3.
1:34
Then we also can use MRI for staging.
1:39
And the staging will help us identify not only
1:43
how big the tumor is, but also its histologic
1:47
character, because there's a correlation between
1:50
the Gleason score and the appearance on MRI.
1:54
Now let's go back to surveillance for a minute.
1:57
Surveillance is used in
1:58
Tier 1 low-risk individuals.
2:01
So what does that give you?
2:04
Well, if you can survey the prostate gland
2:07
and assure that there's not an aggressive
2:10
lesion and use a conservative method for
2:13
following the gland, you avert the potential
2:15
complications of intervention on the prostate
2:19
gland with all the techniques that are
2:20
available out there, starting with surgery.
2:23
With surgery, the risk of having some
2:27
ejaculatory dysfunction is as high as 60%.
2:30
The risk of incontinence or
2:32
leaking is as high as 30%.
2:36
So if you don't need a procedure for an
2:38
aggressive lesion, you shouldn't have one.
2:40
And in the past, we have been operating
2:42
on cancers that are less aggressive.
2:46
So we've got surveillance, which can
2:48
prevent you from having a lesion.
2:50
An unnecessary procedure, probably
2:52
the most important indication of MRI
2:54
by far, and then second is staging.
2:58
And staging helps you not only decide the
3:01
character of the tumor but also what to do.
3:04
Because if the stage is later stage, that's
3:06
a different treatment than if it's early
3:09
stage, even if they are both aggressive.
3:13
So we've already talked about avoiding
3:15
unnecessary surgery; let's take the converse.
3:18
You've got somebody with a rising PSA, and we know
3:21
that the PSA goes up with age because the normal
3:24
gland gets bigger, more normal gland, more PSA.
3:28
So it may be a matter of how fast it rises.
3:32
But the converse that we're referring
3:34
to is, what if the PSA is rising and
3:37
there really is an aggressive cancer?
3:39
How good is MRI at picking
3:40
up Gleason 8s, 9s, and 10s?
3:43
Really, really good.
3:46
How good is it at picking up
3:48
Gleason 1s, 2s, 3s, 4s, 5s?
3:51
Not so good.
3:53
And that's a good thing.
3:55
Because we're not picking up, we're not
3:57
registering a lot of these smaller or
4:00
less aggressive cancers that should be.
4:03
Surveyed for conversion to more aggressive
4:06
character, which MRI does really, really well.
4:10
MRI is used for biopsy planning and overlay.
4:14
So instead of going into a gland, going through
4:17
the rectum from the back here, and just randomly
4:20
putting a needle in and saying, "Okay, I'll take 12
4:22
samples, one here, one here, one here," and so on.
4:26
With MRI, you have directed access to that nodule,
4:30
you overlay it on the ultrasound using it as a
4:34
map, and you can go directly to that locus and put
4:37
your needle right where you see the abnormality.
4:40
And the MR far more accurately shows you
4:44
these loci than ultrasound ever could.
4:48
So you have this very nice correlation
4:50
between MR, truce, and
4:52
where your needle should go.
4:55
On top of that, you can take three-dimensional
4:57
MRI, 3D MRI with thin sections, and you can
5:01
volumetrically take a nodule, and then on
5:04
a series of axial slices, you can simply
5:06
trace the outside of the nodule from one
5:09
slice to the next and get a volume of
5:12
tumor, and further assist the accuracy
5:16
of that transurethral biopsy
5:18
done under sonographic biopsy.
5:22
The other thing you can use MRI for is recurrence.
5:26
MR does pretty well in patients that
5:29
have had prior partial treatments,
5:33
including subtotal prostatectomies.
5:37
Prostatectomies, which is a more complete
5:39
treatment. But many of the other treatments that
5:42
include laser, heat ablation, extracorporation,
5:47
and other newer techniques that alter the
5:51
architecture of the prostate, but there
5:53
are, there are methods to assess tumor
5:56
recurrence that we'll discuss in a minute.
5:58
So we've got surveillance is probably the
6:02
most important aspect of MRI that's unique.
6:07
The second most important is directing
6:10
transurethral ultrasonographic biopsy.
6:13
Probably the third most important is staging.
6:17
And all of these combined will allow you
6:19
to avoid unnecessary surgery or intervene
6:22
if you need to intervene, if you've got
6:24
the MR correlate of a Gleason tumor,
6:26
eight, nine, or ten.
6:28
And we'll discuss what that correlate is.
6:31
We also said that we're going to survey
6:34
individuals that have Tier 1 disease
6:37
or lower-grade types of disease.
6:40
There'll be three tiers and we're going to
6:42
discuss those tiers in a separate section.
© 2024 Medality. All Rights Reserved.